Nitromist

prophylaxis of Angina pectoris, Congestive Heart Failure, Chest Pain + 10 more

Treatment

16 Active Studies for Nitromist

What is Nitromist

Nitroglycerin

The Generic name of this drug

Treatment Summary

Nitroglycerin is a special medication used to treat chest pain, high blood pressure and anal fissures. It comes in different forms - spray, tablets, intravenous, extended-release tablets, and an ointment. The ointment form was approved by the FDA in 1955. It is currently manufactured by Pfizer and other companies, depending on the dosage form.

Nitroglycerin

is the brand name

image of different drug pills on a surface

Nitromist Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nitroglycerin

Nitroglycerin

1981

182

Effectiveness

How Nitromist Affects Patients

Nitroglycerin helps to relax the blood vessels, increasing blood flow to the heart and decreasing the amount of work the heart has to do. Nitroglycerin can also stop spasms in the coronary arteries, reducing the pressure in the arteries and lowering the blood pressure. However, taking nitroglycerin for too long can cause its effects to wear off, meaning it won't work as well as it used to. This may be due to an enzyme in the body being affected, and can lead to pro-oxidant effects, weak blood vessels, and an increased sensitivity to substances that cause vasoconstriction.

How Nitromist works in the body

Nitroglycerin works in the body to relax the muscles in blood vessels. It does this by turning into nitric oxide, a chemical that triggers the muscle relaxation. This leads to more space in the vessels, allowing more blood to flow and reducing pressure. Nitric oxide also activates a cascade of other chemicals that encourage relaxation. In addition, nitric oxide may also target natriuretic peptide receptors to further relax the muscles.

When to interrupt dosage

Condition

Dosage

Administration

Chest Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Coronary Disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Anal Fissure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

induction of Intraoperative Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

insufficient response to beta-blockers

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

nitroglycerin

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Angina Pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Congestive Heart Failure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypertensive disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

prophylaxis of Angina pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Myocardial Infarction

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Warnings

Nitromist has eleven contraindications, therefore it should not be used when struggling with any of the conditions outlined in the following table.

Nitromist Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nitroglycerin may interact with Pulse Frequency

Cardiac Tamponade

Do Not Combine

Pulse Frequency

Do Not Combine

Hypovolemic Shock

Do Not Combine

Anemia

Do Not Combine

Pick Disease of Heart

Do Not Combine

Pulse Frequency

Do Not Combine

Acute Circulatory Failure

Do Not Combine

Intracranial Hypertension

Do Not Combine

Cardiomyopathy, Restrictive

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Nitromist.

Common Nitromist Drug Interactions

Drug Name

Risk Level

Description

Amediplase

Major

The therapeutic efficacy of Amediplase can be decreased when used in combination with Nitroglycerin.

Amifostine

Major

Nitroglycerin may increase the hypotensive activities of Amifostine.

Desmoteplase

Major

The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Nitroglycerin.

Reteplase

Major

The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.

Riociguat

Major

Nitroglycerin may increase the hypotensive activities of Riociguat.

Nitromist Toxicity & Overdose Risk

The toxic dose of nitroglycerin in rats is 105 mg/kg if taken orally and 23.2 mg/kg if taken intravenously. Overdosing on nitroglycerin can cause severe low blood pressure, headache, dizziness, palpitations, flushing and cold skin, nausea, vomiting, difficulty breathing, slow pulse, confusion, paralysis, seizures, and possibly death. Methemoglobinemia, a rare side effect of nitroglycerin, can be treated with methylene blue unless the patient has a known G-6-PD deficiency. There is no known antidote for nitroglycerin overdose

image of a doctor in a lab doing drug, clinical research

Nitromist Novel Uses: Which Conditions Have a Clinical Trial Featuring Nitromist?

38 active studies are currently investigating the potential of Nitromist to prophylactically treat Gastroesophageal variceal hemorrhage, Hypotension and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pain

0 Actively Recruiting

prophylaxis of Angina pectoris

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

induction of Intraoperative Hypotension

0 Actively Recruiting

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Anal Fissure

1 Actively Recruiting

Phase 1

Hypotension

0 Actively Recruiting

insufficient response to beta-blockers

0 Actively Recruiting

Angina Pectoris

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

nitroglycerin

0 Actively Recruiting

Nitromist Reviews: What are patients saying about Nitromist?

5

Patient Review

7/6/2011

Nitromist for Angina

This medication has a long shelf life and is fast acting. I haven't found anything better on the market.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nitromist

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is NitroMist used for?

"NitroMist is used to treat or prevent attacks of chest pain by widening blood vessels, which increases blood flow and oxygen to the heart."

Answered by AI

Can you take too much nitroglycerin?

"If you take too much of this drug, you could have dangerous levels of it in your body. An overdose of this drug can cause throbbing headaches and confusion."

Answered by AI

What does nitroglycerin treat?

"Nitroglycerin sublingual tablets work by relaxing blood vessels and increasing blood flow to the heart, which helps to prevent or relieve episodes of angina. The tablets are typically used before activities that may trigger an episode of chest pain, so that the angina can be prevented before it starts."

Answered by AI

What is lingual aerosol?

"Nitrolingual Pumpspray is used to widen blood vessels and improve blood flow in order to prevent chest pain."

Answered by AI

Clinical Trials for Nitromist

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Nitromist clinical trials?

We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.
Go to Trials
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA

The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Lipika Samal, MD, MPH

Have you considered Nitromist clinical trials?

We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.
Go to Trials
Image of Columbia University Medical Center/ NewYork Presbyterian Hospital in New York, United States.

CTO PCI for Chronic Total Occlusions

18+
All Sexes
New York, NY

Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience

Waitlist Available
Has No Placebo

Columbia University Medical Center/ NewYork Presbyterian Hospital

Margaret B Mcentegart, PhD

Have you considered Nitromist clinical trials?

We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.
Go to Trials